January 23, 2008 — Genetic variations among patients with remitting-relapsing multiple sclerosis (RMSS) may help predict which individuals are likely to respond to interferon-beta therapy. Using a ...

Monoclonal antibody DMTs, especially anti-CD20 therapies, effectively prevent relapses but have limited impact on progressive MS. Progressive MS involves compartmentalized CNS inflammation, with ...

Immediately after occupational therapy (OT), people with multiple sclerosis may show small improvements in daily functioning and mental health-related quality of life (HR-QoL), but OT may have little ...

STOCKHOLM ― Until their mid to late 30s, some people with multiple sclerosis (MS) can better compensate for damage to their central nervous system, new evidence suggests. Thereafter, at about age 40, ...

A stem cell treatment commonly used for blood cancer appears effective in treating one form of MS The treatment has been available since the 1990s but questions about safety and difficulty have ...

A medication used to treat MS also has a beneficial effect on the composition of the intestinal flora, according to researchers. Conversely, the gut flora also plays a role in which side effects occur ...

JT Lew, PharmD, MBA, managed care pharmacist at MultiCare Health System, spoke to the impacts of processes such as prior authorization and step therapy requirements in the realm of multiple sclerosis ...

The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple ...